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Previous studies have shown that serotonin neurons play an important role in the induction and maintenance of L-DOPA-
induced dyskinesia in animals with lesion of the nigrostriatal dopamine system. Patients with Parkinson’s disease that receive
transplants of foetal ventral mesencephalic tissue, the graft cell preparation is likely to contain, in addition to dopamine
neurons, serotonin neurons that will vary in number depending on the landmarks used for dissection. Here, we have studied
the impact of grafted serotonin neurons—alone or mixed with dopamine neurons—on the development of L-DOPA-induced
dyskinesia in rats with a partial 6-hydroxydopamine lesion of the host nigrostriatal projection. In these rats, which showed only
low-level dyskinesia at the time of transplantation, serotonin grafts induced a worsening in the severity of dyskinesia that
developed during continued L-DOPA treatment, while the dopamine-rich graft had the opposite, dampening effect. The detri-
mental effect seen in animals with serotonin neuron grafts was dramatically increased when the residual dopamine innervation
in the striatum was removed by a second 6-hydroxydopamine lesion. Interestingly, rats with grafts that contained a mixture of
dopamine and serotonin neurons (in  2:1) showed a marked reduction in L-DOPA-induced dyskinesia over time, and the
appearance of severe dyskinesia induced by the removal of the residual dopamine innervation, seen in the animals with
transplants of serotonin neurons alone, was blocked. FosB expression in the striatal projection neurons, which is associated
with dyskinesias, was also normalized by the dopamine-rich grafts, but not by the serotonin neuron grafts. These data indicate
that as long as a sufﬁcient portion, some 10–20%, of the dopamine innervation still remains, the increased host
serotonin innervation generated by the grafted serotonin neurons will have limited effect on the development or severity of
L-DOPA-induced dyskinesias. At more advanced stages of the disease, when the dopamine innervation of the putamen is
reduced below this critical threshold, grafted serotonin neurons are likely to aggravate L-DOPA-induced dyskinesia in those
cases where the dopamine re-innervation derived from the grafted neurons is insufﬁcient in magnitude or do not cover the
critical dyskinesia-inducing sub-regions of the grafted putamen. We conclude that it is not the absolute number of serotonin
neurons in the grafts, but the relative densities of dopamine and serotonin innervations in the grafted striatum that is the critical
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For Permissions, please email: journals.permissions@oxfordjournals.orgfactor in determining the long-term effect of foetal tissue graft, beneﬁcial or detrimental, on dyskinesia in grafted Parkinson’s
disease patients.
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Introduction
Dyskinesia is a problematic side-effect of L-DOPA therapy in
patients with Parkinson’s disease and has also emerged as a
potentially serious adverse effect induced by dopamine (DA)
neuron transplants in patients that have undergone cell replace-
ment therapy (Freed et al., 2001; Hagell et al., 2002; Olanow
et al., 2003). In the clinical trials conducted so far, the effect of
foetal DA neuron transplants on L-DOPA-induced dyskinesia has
been variable. In some patients a signiﬁcant reduction has been
observed, while in others the dyskinesias have been unaffected or
even made worse (Widner et al., 1992; Defer et al., 1996; Hagell
et al., 1999; Hauser et al., 1999; Brundin et al., 2000). Moreover,
in two placebo-controlled double-blind trials (Freed et al., 2001;
Olanow et al., 2003), a signiﬁcant number of grafted patients
have developed off-state dyskinesias not present before transplan-
tation. These results have come as a surprise to scientists working
with foetal cell transplantation in animal models of Parkinson’s
disease since the experimental work has indicated that functional
DA neuron grafts should be quite effective in dampening L-DOPA-
induced dyskinesias in the rat Parkinson’s disease model (Lee
et al., 2000; Steece-Collier et al., 2003; Carlsson et al., 2006,
2007; Lane et al., 2006; Maries et al., 2006). Prior to the reports
from the double-blind trials, no signs of graft-induced dyskinesias
had ever been observed or reported in either rodent or primate
models of Parkinson’s disease. Notably, however, none of the
transplant studies in rat and monkey Parkinson’s disease models
that formed the basis for the clinical trials had been performed in
L-DOPA-treated and dyskinetic recipients.
Previous studies have suggested that discrepancies in
the composition of the grafts, the inclusion of serotonin neurons
in the graft cell preparation, in particular, may contribute to the
variable outcome in grafted Parkinson’s disease patients (Carlsson
et al., 2007). In addition to DA neurons, the ventral mesencepha-
lic (VM) tissue grafts are known to contain also serotonin neurons,
and the number of these cells can vary greatly depending on the
landmarks used for dissection. When present in larger numbers
serotonin neurons are effective in inducing a widespread seroto-
nergic hyperinnervation of the host striatum (Takeuchi et al.,
1991; Wright et al., 1991; Ishida et al., 1998; Carlsson et al.,
2007), and in rats with already established L-DOPA-induced dys-
kinesias. We have shown that serotonin neuron transplants will
induce a progressive worsening of dyskinesia over time, without
any improvement in the underlying parkinsonian motor impair-
ments (Carlsson et al., 2007).
Serotonin neurons are particularly interesting since they have
the ability to synthesize, store and release DA, formed from
exogenous L-DOPA, but due to the lack of any autoregulatory
feedback control the DA released from serotonin terminals will
show excessive swings in response to repetitive, intermittent
L-DOPA treatment (Arai et al., 1994, 1995; Maeda et al., 2005;
Carta et al., 2007). Such dysregulated release of L-DOPA-derived
DA is likely to be the main trigger of dyskinesia in L-DOPA-primed
animals (Carta et al., 2007), and may also play a role in
Parkinson’s disease patients undergoing long-term L-DOPA ther-
apy (de la Fuente-Fernandez et al., 2001, 2004). Serotonin neu-
rons, if present in large numbers in the graft cell preparation, may
thus have a detrimental effect on the development of L-DOPA-
induced dyskinesias in grafted patients, and possibly also make
the patients more prone to develop graft-induced off-state
dyskinesias.
The present study was designed to clarify the impact of serotonin
neuron-containing foetal tissue grafts, in the presence or absence of
DA neurons, on the evolution of dyskinesia in L-DOPA-primed rats
with partial 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal
DA system, i.e. in rats that exhibit no or low-level L-DOPA-induced
dyskinesia at the time of transplantation. After a 3-month period of
continued L-DOPA treatment these same rats received a second
6-OHDA lesion aimed at removing the remaining forebrain
DA projection, and in some cases also a lesion of the host serotonin
system, so as to simulate the situation when grafted patients experi-
ence a severe loss of residual DA neurons, in combination with or
without a concomitant loss of serotonin neurons. The results show
that grafted serotonin neurons indeed can induce a severe worsening
of L-DOPA-induced dyskinesias in previously non-dyskinetic or mildly
dyskinetic rats, but that the effect is critically dependent on the pres-
ence or absence of a spared DA innervation, and the extent of the
graft-derived DA innervation, in the host striatum.
Materials and Methods
Animals
A total of 198 adult female Sprague–Dawley rats (225–250g; B&K
Universal, Stockholm, Sweden) were used, and housed under standard
12:12h light:dark cycle and ad libitum access to food and water. All
surgical and behavioural procedures were approved by the Ethical
Committee for use of laboratory animals in the Lund-Malmo ¨ Region.
Experimental design
The experiment was conducted in three stages, as outlined in Fig. 1.
In Stage I (induction phase) all animals received a unilateral intras-
triatal 6-OHDA lesion in order to achieve a partial depletion of the
320 | Brain 2009: 132; 319–335 T. Carlsson et al.nigrostriatal DA pathway (Kirik et al., 1998). About 5–6 weeks later
the animals were screened using amphetamine-induced rotation
(2.5mg/kg) and 129 rats that exhibited more than six fullbody
turns/min, towards the lesioned side, were selected and treated daily
with L-DOPA (6mg/kg, s.c., Research Organics, Cleveland, OH, USA)
in combination with the decarboxylase inhibitor benserazide hydro-
chloride (10mg/kg; Sigma-Aldrich) for 25 days to induce stable abnor-
mal involuntary movements (AIMs). Out of 80 animals that exhibited
AIMs, 60 animals with a generally low level of dyskinesia (total mean
integrated AIM scores: 152 10) were included in the study and allo-
cated into four balanced groups. In addition, ﬁve L-DOPA-naı ¨ve rats
[Les-Ctrl (Drug-Naı ¨ve)] were included as a second control group.
About 12–14 weeks post-lesion, three of the groups received single
cell suspension grafts containing either serotonin neuroblasts (5-HT,
n=16), DA neuroblasts (DA narrow, n=15) or a mixture of DA and
serotonin neuroblasts (DA wide, n=15), obtained from the VM region
of E14 rat embryos, as described (Carlsson et al., 2007). The fourth
group was sham-operated and included as control [Les-Ctrl (L-DOPA,
n=14)]. In addition, 10 animals that had not developed any dyskinesia
during the L-DOPA treatment (AIM score=0) were included in the
study; half of them received grafts of serotonin neuroblasts,
as above [Non-Dys (5-HT)], while the other ﬁve were sham-operated
[Non-Dys (Sham)].
In Stage II the L-DOPA treatment was reinstated 1 week after trans-
plantation at a maintenance regimen of twice-weekly injections (main-
tenance phase), in the four dyskinetic groups and the two ‘non-
dyskinetic’ animal groups, while the Les-Ctrl (Drug-Naı ¨ve) animals
received saline injections. AIMs were evaluated at 3, 6 and 10
weeks after transplantation, followed by assessment of graft-induced
functional recovery in the cylinder and amphetamine-induced rotation
tests.
In Stage III, 14 weeks after transplantation, half of the animals in
the DA narrow, DA wide, 5-HT and Les-Ctrl (L-DOPA) groups and all
10 ‘non-dyskinetic’ animals in the Non-Dys (5-HT) and Non-Dys
(Sham) groups, received a second 6-OHDA lesion, this time in the
medial forebrain bundle (MFB), in order to completely remove the
nigrostriatal pathway. The other half, and all animals in the Les-Ctrl
(Drug-Naive) group, received only a sham-operation, as a burr hole in
the skull. After a 2-week drug-free period daily L-DOPA treatment
(6mg/kg) was resumed for an additional 14 days and occurrence of
dyskinesias was analysed at days 1, 7 and 14. Forelimb use in the
cylinder test, and tests of rotation and dyskinesia in response to
either L-DOPA or apomorphine, were performed at 5–6 weeks after
the MFB lesion (at 19–20 weeks after grafting). The rats in the Non-
Dys (5-HT) and Non-Dys (Sham) groups received, at 8 weeks after the
MFB injection, an injection of 5,7-dihydroxytryptamine (5,7-DHT) into
the MFB, in order to deplete the intrinsic serotonin system in the
striatum on the lesion and grafted side, and tested for L-DOPA-and
apomorphine-induced dyskinesia and rotation. The brains were pro-
cessed for immunohistochemistry at 21 or 25 weeks post-grafting.
Toxin lesions
Toxin injections were conducted under general anaesthesia (20:1 mix-
ture of Fentanyl and Dormitor, i.p.). For the ﬁrst partial DA lesion
28mg of 6-OHDA (3.5mg/ml, free base, in 0.2mg/ml ascorbic acid;
Sigma–Aldrich), was distributed over four sites in the striatum (7mg/
site) at (i) AP: +1.3mm, ML:  2.6mm; (ii) AP: +0.4mm, ML:
 3.2mm; (iii) AP:  0.4mm, ML:  4.2mm; (iv) AP:  1.3mm, ML:
 4.5mm, all  5.0mm below the dura and tooth-bar set at 0.0. For
the second, complete DA lesion, 14mg of 6-OHDA (3.5mg/ml, free
base) was injected into the MFB at AP:  4.4mm, ML:  1.2mm
Fig. 1 Experimental design. In Stage I all animals received a unilateral intrastriatal 6-OHDA lesion in order to obtain a partial lesion of
the nigrostriatal DA pathway. Animals displayed46 fullbody turns/min, towards the lesioned side in the amphetamine (amph) rotation
test were selected. These animals, excluding ﬁve rats that were included as a saline control group [Les-Ctrl (Drug-Naı ¨ve)], were treated
daily with L-DOPA (6mg/kg; in combination with 10mg/kg benserazide hydrochloride) for 25 days to induce stable dyskinesia
(Induction phase). Sixty animals that displayed low levels of dyskinesia (total mean integrated AIM scores: 152 10) were ﬁnally
included in the study and allocated into four balanced groups. At 12–14 weeks after the ﬁrst intrastriatal DA lesion, three of the groups
received single cell suspension grafts (Trpl), containing serotonin neuroblasts (5-HT, n=16), DA neuroblasts (DA narrow, n=15), or a
mixture of DA and serotonin neuroblasts (DA wide, n=15). The fourth group was sham-operated and included as a dyskinetic control
group [Les-Ctrl (L-DOPA), n=14)]. In Stage II twice-weekly L-DOPA treatment was reinstated 1 week after transplantation
(Maintenance phase), in the four dyskinetic groups, while the Les-Ctrl (Drug-Naı ¨ve) animals receive vehicle. In this stage dyskinesias
were evaluated at 3, 6 and 10 weeks after transplantation surgery. In Stage III, half of the animals in the DA narrow, DA wide, 5-HT
and Les-Ctrl (L-DOPA) groups received a second 6-OHDA lesion, in the medial forebrain bundle (MFB), in order to completely lesion
the nigrostriatal pathway, while the other half [and all animals in the Les-Ctrl (Drug-Naive)] received only a sham-operation. After a
2-week drug-free period daily L-DOPA treatment (6mg/kg) was resumed for an additional 14 days and dyskinesias were evaluated at
days 1, 7 and 14. L-DOPA-, apomorphine (apo)- and amphetamine (amph)-induced rotation tests, as well as forelimb use in the
cylinder test, were performed at different time-points after lesion and transplantation, as indicated.
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lesions were performed by injecting 10mg 5,7-DHT creatine sulphate
(5mg/ml, free base; Sigma-Aldrich), dissolved in 0.02% ascorbic acid
into the MFB at AP:  3.0mm and ML:  1.6mm, from bregma,
 7.8mm below dura; tooth-bar:  3.3. All injections were made at a
rate of 1ml/min, and the needle was kept in place for additional
3min before retracted.
Transplantation surgery
The graft cell preparations were obtained from E14 rat embryos and
prepared as described in Carlsson et al. (2007), with the exception
that the rostal and caudal landmarks for the DA narrow grafts were
moved about 0.5mm rostral, in order to minimize the inclusion of
serotonin neuroblasts. The DA narrow, DA wide and 5-HT cell suspen-
sions had a ﬁnal adjusted concentration of 128000, 130000 and
120000 cells/ml, respectively. The rats were mounted in the stereo-
taxic frame with a 5ml Hamilton syringe ﬁtted with a glass capillary (ø
60–80mm). About 120000–130000 cells were injected as two 0.5ml
deposits, at DV  5.0mm and  4.0mm (below dura), through a single
needle penetration, at AP: +0.2mm and ML:  3.5mm; tooth-bar: 0.0.
After the second deposit the syringe was kept in place for an addi-
tional 3min before retracted. Using trypan blue viability staining in a
counting chamber, the cell viability of all cell suspensions after trans-
plantation was estimated to 495%.
Behavioural analyses
Drug-induced rotation
Rotation in response to amphetamine (2.5mg/kg, i.p.), apomorphine
(0.05mg/kg, s.c.) or L-DOPA (6mg/kg, s.c.) was recorded in auto-
mated rotometer bowls (AccuScan Instrument Inc., Columbus, OH,
USA) over 90min (for amphetamine and L-DOPA) or 60min (for apo-
morphine) and expressed as net full body turns per minute, with
negative values indicating rotation away from the lesion side.
Cylinder test
Spontaneous forelimb use was evaluated in the cylinder test (Schallert
and Tillerson, 1999; Kirik et al., 2001). The rats were placed individu-
ally in a glass cylinder (20cm in diameter), and video ﬁlmed while
performing 20–25 weight-shifting movements of the forepaws in con-
tact with the cylinder wall. The numbers of left or right forepaw con-
tacts were scored by an observer blinded to the animals’ identity and
presented as left (impaired) touches in percentage of total touches.
Normal rats will score 50% in this test.
L-DOPA-induced dyskinesia
AIMs, resembling peak-dose dyskinesias in patients, were induced by
daily injections of L-DOPA methyl ester (6mg/kg, s.c., with 10mg/kg
benserazide hydrochloride; Sigma-Aldrich), and shifted to a maintenance
regimen of twice-weekly L-DOPA injections at the same dose (6mg/kg)
for 16 weeks (Stages I–II). A new 2-week daily L-DOPA challenge was
performed after the second 6-OHDA lesion (Stage III). Pre-grafting scores
were calculated as means of three consecutive tests (3 days apart) and
the 3, 6 and 10 weeks post-grafting scores as means of two test sessions
(4 days apart). The post-MFB lesion scores, at days 1, 7 and 14, are from
single observations.
The AIMs were scored every 20min (for at least 3h, until no AIMs were
observed) according to a rat dyskinesia scale, where severity scores from 0
to 4 were given for four dyskinetic subtypes according to topographic
distribution as forelimb, orolingual, axial and locomotive behaviours, as
described by Lee et al. (2000), with minor modiﬁcations (Winkler et al.,
2002; Carlsson et al., 2006). In the rat model, the ﬁrst components to
appear after L-DOPA treatment are the limb and orolingual dyskinesias. As
the chronic treatment continuous the axial dyskinesias get more and more
apparent. In animals with intrastriatal lesions, where the dyskinesia is less
severe as compared to a MFB lesion, the limb and orolingual dyskinesias
are the main behaviours observed after L-DOPA treatment. Animals with
MFB lesions (where the DA denervation is more complete) develop more
severe dyskinesias and the axial component becomes more prominent.
While the limb and oroligual movements are viewed as hyperkinesia, the
axial component is clearly of a different, dystonic type. Enhanced normal
behaviours, such as grooming, gnawing, rearing and snifﬁng, could be
observed, but these were not included in the rating. The data are pre-
sented as integrated AIM scores, calculated as the area under the curve
over the whole test session.
Apomorphine-induced dyskinesia
Dyskinesias induced by apomorphine (0.05mg/kg; Sigma–Aldrich)
were assessed at 20 weeks after transplantation and for the ‘non-dys-
kinetic’ groups [Non-Dys (5-HT) and Non-Dys (Sham)] at 3 weeks
after the 5,7-DHT lesion. AIMs were scored every 10 mins for 90
mins, using the same rating scale as for L-DOPA-induced dyskinesia,
and presented as the integrated AIM score for the whole observation
period.
Histological analyses
At 21–25 weeks post-transplantation (5 weeks after the 5,7-DHT lesion in
the ‘non-dyskinetic’ groups) the animals were anesthetized by an overdose
of sodium pentobarbital, and perfused transcardially with 50ml saline, fol-
lowed by 250ml of ice-cold 4% PFA in 0.1M phosphate buffer (pH 7.2–
7.6). The brains were postﬁxed in the same ﬁxative for 2–3h, placed in
25% sucrose for at least 24h and sectioned on a freezing microtome at
35mm. The sections were divided into eight series and stored (at  20 C)
until further processing.
Immunohistochemistry
Immunostainings were performed as described (Carlsson et al., 2007)
using primary antibodies against tyrosine hydroxylase [TH; mouse anti-
TH (MAB318, 1:2000; Chemicon)], serotonin transporter [SERT; mouse
anti-SERT (MAB1564, 1:1000; Chemicon)], serotonin [rabbit anti-ser-
otonin (1:10000; Immunostar Inc.)] and FosB [goat anti-FosB (SC-48X,
1:15000; Santa Cruz)], with appropriate secondary antibodies (for TH
and SERT: horse anti-mouse BA2001; for serotonin: goat anti-rabbit
BA1000; and for FosB: horse anti-goat BA9500; Vector Laboratories).
SERT staining was intensiﬁed by addition of nickel ammonium
(2.5mg/ml) in the 3,30-diaminobenzidine solution. For FosB staining,
0.25% Triton X100 was added in all steps, including rinses. To minimize
background, the FosB antibody was diluted 1:50 and pre-incubated with
untreated forebrain sections (from control rats) for 3–5h.
Stereology
The number of TH- and serotonin-positive cells present in
the transplants were estimated using the Computer Assisted
Stereological Toolbox (CAST) module in VIS software (Visiopharm
A/S, Denmark) and a 60  magniﬁcation oil lens (numerical aperture:
1.40) as described (Kirik et al., 1998; Carlsson et al., 2007). The total
numbers of cells were estimated according to the optical fractionator
(West, 1999).
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TH- and SERT-positive ﬁbre densities were determined by optical den-
sity measurements from the stained sections using the Image
J software platform version 1.38  for Mac OSX (National Institutes
of Health, USA, http://rsb.info.nih.gov/ij/) as described (Carlsson
et al., 2007). Measurements were made from the rostral (Ros) and
caudal (Cau) parts of the head of the caudate–putamen, including two
sub-areas, the rostro–dorsolateral (Rdl) and caudal-lateral (Cl) regions,
as illustrated in Fig. 8A and F, and expressed as per cent of the control
side. The Ros and Rdl values give the means of two sections from the
rostral striatum (AP: +1.60 and +1.00), and the Cau and Cl values of
two sections from the caudal striatum (AP: +0.20mm and  0.30)
(Paxinos and Watson, 2005).
Estimations of FosB-positive cell numbers
To evaluate changes in FosB expression in the striatal target neurons
a single L-DOPA injection was given at 48h before sacriﬁce. The total
number of FosB-positive cells was evaluated by Image J software. Two
high-resolution images were captured, corresponding to the rostral and
caudal aspect of the head of striatum (1.00 and  0.30mm from bregma)
using Scanscope GL system with Imagescope v8.2 software. The same
four striatal regions as above (Ros, Rdl, Cau and Cl) were analysed. A
threshold was set to exclude basal grey matter background staining, and
the total number of cells that appeared with higher optical density was
automatically calculated by the software.
Statistical analysis
All statistical group comparisons were conducted using one-way
ANOVAs, Two-way repeated measures ANOVA or un-paired t-test
where appropriate. Post hoc analyses were performed using
Dunnett’s test or Tukey HSD analysis. For all comparisons statistical
signiﬁcance was set at P40.05, and the signiﬁcant statistics are
reported in respective ﬁgure legend. All comparisons were performed
using JMP Statistical software version 5.0.1.2 (SAS Institute Inc., Cary,
NC, USA).
Results
The experiment was conducted in three stages (Fig. 1). In Stage I,
129 rats with partial, intrastriatal 6-OHDA lesions were given daily
injections of L-DOPA (6mg/kg, plus 10mg/kg benserazide) for 25
days to develop a stable level of L-DOPA-induced dyskinesia. All
animals exhibited 46 turns/min in the amphetamine rotation test
(2.5mg/kg), which is consistent with a 70–90% loss of the nigral
DA neurons (Kirik et al., 1998; Winkler et al., 2002; Breysse et al.,
2007). In Stage II, 60 of the L-DOPA-treated rats that had devel-
oped a low level of L-DOPA-induced dyskinesia (total AIM scores
152 10) were allocated to four balanced groups that received
intrastriatal grafts containing either DA neurons only (DA narrow,
n=15); serotonin neurons only (5-HT, n=16); a mixture of DA
and serotonin neurons (DA wide, n=15); or sham surgery [Les-
Ctrl (L-DOPA), n=14]. An additional 10 rats that showed no signs
of dyskinesia at the end of the 25-days L-DOPA treatment period
(AIM score=0) were given serotonin neuron transplants [Non-Dys
(5-HT), n=5] or sham surgery [Non-Dys (Sham), n=5]. All rats
received continued L-DOPA treatment (6mg/kg, twice weekly)
and the changes in L-DOPA-induced AIMs were monitored over
the subsequent 10 weeks. In Stage III half of the animals in each
of the four ﬁrst groups, and all 10 rats in the ‘Non-dyskinetic’
groups, received a second 6-OHDA injection, this time in the
MFB, in order to remove the remaining neurons of the nigrostriatal
DA pathway. The impact of this second lesion on the severity of
the L-DOPA-induced dyskinesias was monitored during 14 days of
daily L-DOPA treatment, starting 2 weeks after the MFB lesion.
At sacriﬁce, one animal in the DA narrow and one in the 5-HT
graft group were found to have large necrotic tissue damages in
the cortex, and one animal in the DA wide group had a misplaced
graft extending into the ventral forebrain. These animals were
excluded from the study.
Development of L-DOPA-induced dys-
kinesia in rats with advancing degen-
eration of the nigrostriatal DA pathway
The rats were selected in the pre-test (in Stage I) to exhibit a low
level of L-DOPA-induced dyskinesia prior to transplantation. In
Stage II the non-transplanted lesioned controls [Les-Ctrl (L-
DOPA)] remained mildly dyskinetic after continued L-DOPA treat-
ment, with AIMs limited to repetitive limb and orolingual move-
ments, without any signs of axial (torsive head, neck and trunk)
movements (ﬁlled circles in Fig. 2A-A00). In animals with DA-rich
grafts dyskinesias were almost completely suppressed (79 and
57% reduction in limb and orolingual AIMs at 10 weeks after
transplantation in the DA narrow and DA wide groups, respec-
tively) (open and ﬁlled squares in Fig. 2A-A00). Rats with serotonin
neurons grafts, by contrast, showed a marked, 2.5-fold, increase
in the magnitude of L-DOPA-induced dyskinesia (open triangles in
Fig. 2A). This increase was most prominently due to the appear-
ance of the more severe, dystonia-like axial component, not seen
in any of the other groups (Fig. 2A00).
In Stage III the residual dopaminergic forebrain projections were
removed by an additional injection of 6-OHDA placed in the MFB.
After a 2-week recovery period daily L-DOPA treatment was
resumed for 14 days. In the non-grafted animals [Les-Ctrl (L-
DOPA)] this resulted in a marked increase not only in the overall
magnitude of L-DOPA-induced dyskinesia, as reﬂected in about 4-
fold increase in the total integrated AIM scores (ﬁlled circles in
Fig. 2B and B0), but also in increased severity, as shown by the
appearance of axial dyskinetic movements (Fig. 2B00). In the DA
narrow and DA wide graft groups the dyskinesia scores also
increased over the 2-week L-DOPA treatment period, but the
magnitude remained much below that seen in the non-trans-
planted animals, and the development of the dystonia-like axial
dyskinesias was effectively suppressed (open and ﬁlled squares in
Fig. 2B-B00). In the rats with serotonin grafts (5-HT) dyskinesias
were dramatically increased, from a level of 398 112 in total
integrated AIM scored prior to the second lesion, to 1122 144
after the continued L-DOPA treatment (open triangles in
Fig. 2B-B00). This increase was accompanied by the development
of severe axial dyskinesia in all serotonin-grafted animals
(Fig. 2B00). In contrast, in the animals that received a sham-opera-
tion instead of the second 6-OHDA lesion, dyskinesias remained
unchanged over the L-DOPA treatment period, as compared with
the 10-weeks time-point (Fig. 2C-C00).
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non-dyskinetic rats
In Stage II of the experiment ten L-DOPA-treated but non-dyski-
netic 6-OHDA lesioned rats received either serotonin neuron grafts
[Non-Dys (5-HT), n=5] or sham surgery [Non-Dys (Sham), n=5]
(Fig. 3A). These rats developed no signs of dyskinesia during the
25-day L-DOPA priming period (in Stage I), and they all remained
essentially non-dyskinetic during the second period of L-DOPA
treatment (Post Trpl, Fig. 3B). After the second 6-OHDA lesion,
in the MFB, performed 2-weeks post-transplantation, both groups
developed severe L-DOPA-induced dyskinesia with mean inte-
grated AIM scores of 918 220 and 786 152 for the Non-Dys
(5-HT) and Non-Dys (Sham) groups, respectively (Post MFB lesion
in Fig. 3B), as well as marked turning behaviour in response to low
doses of either apomorphine or L-DOPA (Fig. 3D and E).
Fig. 2 Impact of DA and serotonin grafts with advancing DA neurodegeneration (Stages II and III). L-DOPA-induced dyskinesia was
evaluated before (pre) and at 3, 6 and 10 weeks after the transplantation surgery (A–A00). The Les-Ctrl (L-DOPA) group maintained the
low magnitude of dyskinesias throughout. In the DA-rich grafts (DA narrow and DA wide) the total AIMs scores were progressively
reduced over time, reaching 79 and 57% reduction at 10 weeks respectively, while the serotonin-only graft animals (5-HT) showed
an overall 2.5-fold increase (A–A00). In the 5-HT graft group the more severe axial, dystonia-like, component, not observed in any of
the other groups, became evident at 3 weeks and further increase over the following weeks (A00). After the second 6-OHDA lesion
(in the MFB) daily L-DOPA treatment was re-instated for 2 weeks, and L-DOPA-induced dyskinesia was evaluated at days 1, 7 and 14
(B–B00). In the Les-Ctrl (L-DOPA) group total AIMs score were increased, up to 4-fold (B), seen as an increase in the limb and orolingual
AIMs, and as the appearance of the more severe, dystonia-like, axial component (B0 and B00). Although dyskinesia showed some
increase over time in the DA narrow and DA wide graft groups, the overall AIMs scores remained on a low-to-moderate level. The
5-HT graft group, in contrast, showed a dramatic increase after the MFB lesion, with AIMs scores reaching levels exceeding 1000,
which was marked higher than seen in any of the lesion controls. The groups receiving only sham-operation at the time of the second
6-OHDA lesion, showed no change in dyskinesia compared to their own 10-week post-transplantation scores (C–C00). Asterisk indicates
the different from Les-Ctrl (L-DOPA) group (a sum of dyskinesias at 6 and 10 weeks were calculated). A, A0,A 00,B ,B 0 and B00: One-way
ANOVAs F(3,56)=14.35, F(3,56)=12.56, F(3,56)=11.76, F(3,27)=15.71, F(3,56)=7.21 and F(3,27)=22.15, respectively. For all
comparisons P40.0004. All ANOVAs were followed by Dunnett’s control test.
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induction of dyskinesia in these animals, the selective serotonin
neurotoxin 5,7-DHT was injected into the MFB 8 weeks after
the second 6-OHDA lesion, in order to remove the intrinsic
forebrain serotonin afferents on the lesion and grafted side
(Fig. 3F and G). Consistent with previous data (Carta et al.,
2007) L-DOPA-induced (but not apomorphine-induced) dyskinesia
was completely abolished in the Non-Dys (Sham) animals, but
remained unchanged in the animals with serotonin neuron grafts
in the Non-Dys (5-HT) group (Post 5,7-DHT lesion in Fig. 3B
and C). In the rotation test L-DOPA-induced turning was comple-
tely abolished in the non-grafted Non-Dys (Sham) animals
(0.1 0.1 turns/min) but remained at a high level ( 14.0 3.5
turns/min) in the serotonin graft group (Fig. 3E). Postsynaptic
DA receptor supersensitivity, as reﬂected in the apomorphine-
induced turning response (Fig. 3D), was unaffected by the 5,7-
DHT lesion.
Impact on postsynaptic receptor
supersensitivity
In order to monitor changes in postsynaptic DA receptor super-
sensitivity in the lesioned and grafted animals, dyskinesia and rota-
tional behaviour in response to a low dose of the mixed D1/D2
agonist apomorphine (0.05mg/kg, s.c.) were assessed at 19–20
weeks post-transplantation (Fig. 4). In rats with partial lesions,
apomorphine-induced dyskinesias (limb and orolingual AIMs)
were reduced by 81–86% in the two DA neuron containing
graft groups (DA narrow and DA wide), as compared to the
non-grafted Les-Ctrl group, while the 5-HT graft group remained
Fig. 3 Effect of serotonin grafts, and lesion of the intrinsic serotonin system, in L-DOPA-treated but non-dyskinetic animals. In order
to investigate the effect of serotonin grafts in the presence or absence of an intrinsic serotonin innervation, ‘non-dyskinetic’ animals,
i.e. 6-OHDA lesioned rats that did not show any signs of dyskinesia after the 25-day induction phase, were transplanted with serotonin
grafts or sham-operated and later the intrinsic serotonin ﬁbres were removed by a 5,7-DHT injection in the MFB (A: Experimental
design; B: Post Intrastriatal Lesion). After the transplantation [Non-Dys (5-HT)] or sham surgery [Non-Dys (Sham)] none of the animals
displayed any notable increase in dyskinesia (B: Post Trpl). However, after the second 6-OHDA lesion, placed in the MFB, both groups
displayed severe AIMs of all sub-categories (B: Post MFB lesion). Following the 5,7-DHT lesion dyskinesias in the sham-operated group
were completely abolished, while the dyskinesias seen in the serotonin graft group [Non-dys (5-HT)] remained unchanged (B: Post
5,7-DHT lesion). In agreement, L-DOPA-induced rotation was completely abolished in the sham-operated rats, but unchanged in the
serotonin transplanted animals (E). In contrast to the dyskinesias and rotation induced by L-DOPA, apomorphine-induced dyskinesias
and rotation were both unaffected by the serotonin lesion (C and D). SERT immunohistochemistry revealed an almost complete
denervation of the serotonin ﬁbres in the striatum after the 5,7-DHT lesion (7.2 4.4% of intact side, F), while the transplanted
animals showed extensive re-innervation (108.4 18.2% of intact side, G). Scale bar in F represents 3mm. Asterisk indicates the
different from post MFB. B: One-way ANOVAs: F(3,19)=21.22, P50.0001 and F(3,19)=26.96, P50.0001 for and Non-Dys (Sham)
and Non-Dys (MFB), respectively. E: t-test, P=0.045.
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received the second 6-OHDA lesion, the dyskinesias increased 2-
to 3-fold in both the lesion controls and in the 5-HT graft group,
but remained unchanged, or on a low level, in the DA neuron-
containing graft groups (Fig. 4A, Intrastriatal+MFB).
Similar changes were evident in the apomorphine-induced rota-
tion test (Fig. 4B). Apomorphine-induced rotation, in the direction
contralateral to the lesion, was minimal or absent in the partially
lesioned animals (Intrastriatal+Sham), but became apparent after
the second 6-OHDA lesion (Intrastriatal+MFB). The increased
rotation seen after the second lesion in the lesion controls,
from 0.0 0.1 to  7.0 1.0 turns/min, was blocked by the DA
neuron containing grafts. The 5-HT graft group, by contrast,
showed a 2-fold higher apomorphine-induced rotation, compared
with the lesioned controls [Les-Ctrl (L-DOPA)], after the second 6-
OHDA lesion.
In the L-DOPA-induced rotation test, the animals with partial
lesions showed only minimal response to the L-DOPA (Fig. 4C,
Stage II: Intrastriatal+Sham). After the second lesion the animals
in the Les-Ctrl (L-DOPA) group displayed an increased rotation,
from 0.1 0.1 to  1.8 1.0 turns/min. Strikingly, the 5-HT graft
animals showed an average 6.5-fold higher rotation rate (from
 0.5 0.3 to  11.4 2.1 turns/min) as compared to the lesion
control group, while the response was completely suppressed in
the two DA graft groups (Fig. 4C).
The apomorphine-induced rotation indicates that the increase in
postsynaptic DA receptor supersensitivity that developed in the
lesioned controls after the second lesion was differentially affected
by the two types of graft: normalized in the rats with DA neuron
containing grafts, but made worse by the serotonin neuron
transplants.
Graft-induced functional improvement
The turning bias seen in the amphetamine rotation test, present in
all animals before transplantation, was completely reversed in the
two DA graft groups, but not in the 5-HT graft group after graft-
ing (Fig. 5A). Similarly, the left forelimb use in the cylinder test,
which was reduced to 510% in the lesion control animals, was
restored to normal performance in the DA narrow and DA wide
graft groups (54.7 6.5% and 55.6 6.7% of intact side, respec-
tively) but unaffected by the 5-HT grafts (9.9 4.7% of intact
side; Fig. 5B). Together, these data indicate that functional DA
release, accompanied by reversal of DA receptor supersensitivity
was restored in the grafted striatum in the two groups that had
received DA neuron-containing transplants. However, the func-
tional recovery induced by the DA-rich grafts, seen in Stage II
(Fig. 5B), was partially lost after the second 6-OHDA lesion
(Fig. 5C), which is consistent with previous ﬁndings (Breysse
et al., 2007). Amphetamine-induced rotation after the second 6-
OHDA lesion was not evaluated in the current study, however,
previous data have shown that recovery in rotation by DA
neuron grafts in partial DA lesioned rats is not effected by a
second complete lesion placed in the MFB (Breysse et al., 2007).
Fig. 4 Impact of DA and serotonin grafts on DA receptor supersensitivity with advancing DA neurodegeneration. Apomorphine-
induced dyskinesia (A) and rotation (B) as well as L-DOPA-induced rotation (C) were assessed in order to monitor the development of
postsynaptic DA receptor supersensitivity in the lesioned and grafted animals. In rats with partial lesions (Intrastriatal+Sham), apo-
morphine-induced dyskinesias (limb and orolingual AIMs) were reduced by 81–86% in the two DA neuron containing graft groups (DA
narrow and DA wide), as compared with the non-grafted Les-Ctrl group, while the 5-HT graft group remained unchanged (A). In the
animals that had received the second DA lesion (Intrastriatal+MFB), dyskinesias increased several-fold in both the lesion controls and in
the 5-HT graft group, but remained unchanged, or on a low level, in the DA neuron-containing graft groups. In animals with
intrastriatal lesion only (Intrastriatal+Sham) rotation induced by apomorphine or L-DOPA were not observed in either of the groups
after the intrastriatal 6-OHDA lesion, however the serotonin graft group (5-HT) showed a tendency to increase in rotation away from
the lesion side (B and C). After the second DA lesion (Intrastriatal+MFB), apomorphine- and L-DOPA-induced rotations increased in
both the Les-Ctrl (L-DOPA) and 5-HT groups, but effectively repressed in the DA narrow and DA wide groups (B and C). Interestingly,
L-DOPA-induced rotation showed a dramatic, 6.5-fold increase in the 5-HT graft group compared to the lesion only controls (C).
Asterisk indicates different from Les-Ctrl (L-DOPA) group. A–C: One-way ANOVAs F(3,28)=11.82/F(3,27)=24.35, P50.0001 and
F(3,28)=10.37/F(3,27)=21.05, P50.0001 and F(3,28)=3.77, P50.023/F(3,27)=22.91, P50.0001 for Intrastriatal+Sham/
Intrastriatal+MFB and A–C, respectively. All ANOVAs were followed by Dunnett’s control test.
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In order to monitor postsynaptic changes in the striatal target
neurons in the L-DOPA-treated dyskinetic animals, FosB-protein
expression in the striatum was evaluated 48h after the last L-
DOPA injection. The number of FosB-positive cells, which is
known to be strongly correlated with the magnitude of L-
DOPA-induced dyskinesia in the rat model (Andersson et al.,
1999; Winkler et al., 2002), were counted in the rostral (Ros)
and caudal (Cau) striatum, as well as in two sub-regions, the
rostro–dorsolateral (Rdl) and Caudal-lateral (Cl) areas of the stria-
tal head (Fig. 8A).
In the animals with partial lesions of the nigrostriatal
DA pathway, i.e. the animals that had received intrastriatal
6-OHDA followed by a sham injection in the second surgery
(Intrastriatal+Sham in Fig. 6A–D), FosB was expressed in a
large number of cells on the lesion side, ranging from 926 177
to 1579 168 cells in all four regions analysed (Fig. 6A–D, open
bars). The animals in the DA graft groups (DA narrow and DA
wide) had signiﬁcantly lower numbers of FosB-positive cells in all
four regions (grey bars in Fig. 6A–D), ranging from 136 32 to
517 103, similar to the number observed on the non-lesioned
side (averages of number of cells on the intact side,  SD, are
indicated by the full and dashed horizontal lines in Fig. 6A–D).
In the 5-HT graft group the FosB-positive cell number tended to
exceed that seen in the dyskinetic Les-Ctrl (L-DOPA) controls
(from 1381 242 to 2164 316 cells in the four regions analysed;
black bars in Fig. 6A–D). These differences, however, did not
reach signiﬁcance.
In the animals that received the second 6-OHDA injection
(Intrastriatal+MFB in Fig. 6A–D), FosB expression was further
increased in the non-grafted controls [Les-Ctrl (L-DOPA)], from
1471 241 to 2674 526 cells. Similar high expression levels
were observed in all regions in the 5-HT graft group (from
1838 311 to 2962 613 cells). The animals in the DA graft
groups displayed signiﬁcantly lower expression of FosB protein,
in particular in the Rdl (524 183 and 390 170 cells) and Cl
(372 122 and 431 179 cells) regions, which were not different
from that seen on the contralateral intact side (DA narrow:
P40.11, in all regions; DA wide: P40.14, in all regions, un-
paired t-tests).
Interestingly, in the lesioned control animals FosB-expressing
cells were found mainly in the completely DA denervated areas,
as determined from adjacent TH stained sections (Fig. 6E).
Following the second 6-OHDA lesion the head of striatum was
almost completely devoid of TH-positive innervation and the FosB
expressing cells were widely distributed over large areas of the
striatum (Fig. 6F). In the DA narrow and DA wide groups FosB
expression was completely normalized in the areas reinnervated by
the graft-derived TH-positive ﬁbres (Fig. 6G and H). In the 5-HT
graft group the graft-derived serotonin innervation was unable to
reverse FosB expression; both the number and staining intensity of
the FosB-positive cells tended to be increased, above that seen in
the lesion-only controls, in the areas innervated by the graft-
derived serotonin ﬁbres (compare Fig. 6I and J with E and F).
In the non-dyskinetic animals, that received an addi-
tional unilateral serotonin lesion, the serotonin transplanted group
[Non-Dys (5-HT)] tended to increase in FosB expression in all
Fig. 5 Functional impact of DA and serotonin grafts. Changes in amphetamine-induced rotation were assessed at 11 weeks post-
grafting (A), and forelimb use in the cylinder test at 12 weeks post-grafting (B) and at 5 weeks after the second DA lesion (C). After the
ﬁrst, intrastriatal, lesion all groups displayed a strong amphetamine-induced rotational bias ipsilateral to the lesion side. Following
transplantation the rotation in the DA narrow ( 0.2 0.8 turn/min) and DA wide (0.7 0.9 turn/min) groups were completely
reversed back to normal, while the 5-HT and the Les-Ctrl (L-DOPA) groups were unaffected (19.3 2.3 and 18.5 1.8 turn/min,
respectively). In the cylinder test, which evaluates the rats’ spontaneous forelimb use, all groups were severely impaired and balanced
prior to transplantation (Les-Ctrl (L-DOPA): 11.1 2.0%, DA narrow: 12.5 3.9%, DA wide: 11.5 2.6% and 5-HT: 8.7 2.9% of
intact side). After transplantation the DA neuron graft groups were reversed back to normal performance (DA narrow: 54.7 6.5% and
DA wide: 55.6 5.7% of intact). The 5-HT (9.9 4.7% of intact) and the Les-Ctrl (L-DOPA) (6.1 1.9% of intact) groups were
unaffected. The second 6-OHDA lesion, however, partly removed the beneﬁcial effect seen in the cylinder test in the DA grafted
animals. Dashed lines in B and C represent the performance of a normal, unbiased, animal. Asterisk indicates different from respective
pre-value. (A—B) Two-way repeated measures ANOVAs: Time interactions, F(3,53)=97.99, P50.001 and F(3,53)=62.40, P50.0001,
respectively.
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compared to the sham-operated group [Non-Dys (Sham)], from
1038 134 to 2761 669. This was observed in particular in
the Rdl part [2499 477 versus 1265 158 in the Non-dys
(5-HT) and Non-dys (Sham), respectively, P=0.06, un-paired
t-test]. However, the cell numbers in both groups were compar-
able to respective dyskinetic group, Non-Dys (5-HT) versus 5-HT
group (P40.28 for all regions, un-paired t-test) and Non-Dys
(Sham) versus Les-Ctrl (L-DOPA) group (P50.14 for all regions,
un-paired t-test).
Histological analysis of graft survival
and ﬁbre outgrowth
TH and serotonin immunohistochemistry revealed surviving
grafts in all transplanted animals (Fig. 7A and F). The DA
narrow grafts contained high numbers of TH-positive cells,
3621 459 (3822 825 and 3419 466 in Intrastriatal+Sham
and Intrastriatal+MFB respectively, P=0.68, un-paired t-test),
but virtually devoid of any serotonin-positive neurons. Conversely,
the 5-HT graft group contained high numbers of serotonin
neurons, 2256 308 (1860 298 and 2709 540 in
Intrastriatal+Sham and Intrastriatal+MFB, respectively, P=0.20,
un-paired t-test), with very few TH-positive cells, 19 4 (11 4
and 29 6i nIntrastriatal+Sham and Intrastriatal+MFB, respec-
tively, P=0.04, un-paired t-test). The DA wide grafts, in contrast,
included high numbers of both DA, 3633 501 (2510 524 and
4355 798 in Intrastriatal+Sham and Intrastriatal+MFB, respec-
tively, P=0.16, un-paired t-test), and serotonin neurons,
2307 325 (1929 260 and 2686 585 in Intrastriatal+Sham
and Intrastriatal+MFB, respectively, P=0.27, un-paired t-test),
with an average DA:serotonin neuron ratio of 1.8:1.
The intrastriatal 6-OHDA lesion depleted the TH-positive ﬁbres
in the caudal striatum by more than 90%, while the rostral region
was partly spared ( 20% of normal; Figs 7B–E and 8A). The
second 6-OHDA lesion removed the spared ﬁbres in the whole
striatum (Figs 7B–E and 8B). In the DA narrow and DA wide graft
groups, the transplanted DA neurons restored TH-positive ﬁbre
density in the caudal striatum by 12–14% of normal, while the
rostral parts were overall poorly innervated (Ros: 3–5%, Rdl:
6–9% of intact side; Figs 7B–E, 8C and D).
SERT immunohistochemistry showed that the intrastriatal
6-OHDA lesion had caused a minor damage (19–23%) to the
serotonin innervation in the striatum (Figs 7G, I and 8F). The
second DA lesion led to an additional loss of about one-third of
the SERT-positive striatal serotonin innervation, to 66–69% of
intact side in the rostral and caudal striatum (Figs 7G–J and 8G).
In the 5-HT and the DA wide groups, which contained high num-
bers of serotonin neurons in their grafts, a marked SERT-positive
hyperinnervation was observed at all levels investigated (Figs 7G–J,
8I and J). This hyperinnervation was particularly prominent in the
Rdl region, where the density of SERT-positive ﬁbres was
increased to 178–237% and 171–260% of intact side in the
5-HT and DA wide graft groups, respectively (Fig. 7H).
Interestingly, a localized SERT-positive serotonin hyperinnerva-
tion was observed in the ventrolateral region of the caudal stria-
tum in a signiﬁcant number (9 of 14) of the non-transplanted
animals in the dyskinetic lesion control groups (asterisk in Fig. 8F
and G), both in the animals receiving the second 6-OHDA lesion
(Intrastriatal+MFB; 2 of 7) as well as in the animals receiving only
the partial, intrastriatal lesion (Intrastriatal+Sham; 7 of 7). This
effect was also observed in the DA narrow group, (10 of 14;
Fig. 8H) as well as the Drug-Naı ¨ve (i.e. non-L-DOPA-treated)
lesion control animals (3 of 5). This serotonin hyperinnervation,
however, did not correlate with either the magnitude of dyskine-
sia, or with the pattern of FosB expression, suggesting that this
sprouting response may be induced by the 6-OHDA lesion, inde-
pendent of any L-DOPA treatment. Indeed, close comparison of
adjacent SERT and FosB stained sections showed that regions of
increased density of SERT-positive ﬁbres displayed only
low numbers of FosB-expressing cells.
Discussion
The study was designed to investigate the inﬂuence of serotonin
neuron-containing grafts on the development of L-DOPA-induced
Fig. 6 Effect of DA and serotonin grafts on striatal FosB expression. FosB-positive cells were estimated in the striatum in four
areas corresponding to the rostral, rostro–dorsolateral (Rdl), Caudal and Caudal-lateral (Cl) striatum (Fig. 8A). In the dyskinetic
lesion control animals [Les-Ctrl (L-DOPA)] extensive FosB expression were observed in all regions after the ﬁrst intrastriatal 6-OHDA
lesion (Intrastriatal+Sham; A–D) and was further increased after the second DA lesion (Intrastriatal+MFB; A–D). Increased FosB
expression was mainly observed in DA denervated areas, as seen in the rostro–dorsolateral and caudal regions in the lesion control
group after the intrastriatal lesion (E), and further also in the rostral region after the second 6-OHDA lesion (F). The serotonin neuron-
containing grafts (5-HT) did not show an overall signiﬁcant increase in FosB expression as compared to the lesion-only controls [Les-Ctrl
(L-DOPA)]; individual cases, however, showed a clear tendency to an increase in both number, distribution and staining intensity of the
FosB-expressing cells, as illustrated in I and J. The DA graft groups (DA narrow and DA wide), in contrast, reversed FosB expression
in all regions after the ﬁrst lesion (Intrastriatal+Sham), and expression in the rostro–dorsolateral and caudal areas, close to the grafted
DA cells, were effectively repressed also after the second 6-OHDA lesion (Intrastriatal+MFB; B–D, G and H). However, in the rostral
striatum, which were poorly innervated by TH-positive ﬁbres from the graft, the protein expression were not different from the Les-Ctrl
(L-DOPA) group (Intrastriatal+MFB; A). The horizontal lines in A–D represent the average cell number (full) 1 SD (dashed) on the
intact side (all animals in respective region and lesion). Insets give the total AIM scores for the illustrated animals. Scale bars in
J represent 1mm. Asterisk indicates different from Les-Ctrl (L-DOPA) group. A: One-way ANOVA F(3,28)=10.71, P=0.0001
intrastriatal+MFB; B-D: One-way ANOVAs F(3,28)=12.53, P50.0001, F(3,28)=18.61, P50.0001 and F(3,28)=19.03, P50.0001/
F(3,27)=9.29, P=0.0003, F(3,27)=5.95, P=0.004 and F(3,27)=10.03, P=0.0002 for Intrastriatal+Sham/Intrastriatal+MFB and
B–D, respectively. All ANOVAs were followed by Dunnett’s control test.
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lesions of the nigrostriatal DA pathway, that had developed no or
only low-level dyskinesias at the time of transplantation. Three
months later, the rats were subjected to a second 6-OHDA
lesion, in order to simulate the situation in grafted, mildly dyski-
netic patients when the degeneration of the intrinsic DA system
has progressed further. In Parkinson’s disease patients, disease
progression is accompanied by a progressive worsening of the
L-DOPA-induced peak-dose dyskinesias and a reduction of the
Fig. 7 TH- and serotonin-positive cell numbers and TH- and
SERT-positive ﬁbre innervation in the striatum. The total
number of grafted TH- and serotonin-positive cell in the
striatum was estimated using stereological technique (A and F).
The DA narrow grafts contained high numbers of TH-positive
cells (3621  459) without inclusion of serotonin-positive neu-
rons, and the 5-HT graft group contained high numbers of
serotonin neurons (2256 308), with very few TH-positive
cells (19 4). In the DA wide grafts, high numbers of both TH-
positive (3633 501) and serotonin-positive neurons
(2307 325), were found. The extent of TH- and SERT-posi-
tive ﬁbre innervation was determined, by optical density mea-
surements from the TH and SERT stained sections, for the
rostral and the caudal aspect of the head of the striatum, and
two sub-regions, representing Rostro–dorsolateral (Rdl) and
Caudal-lateral (Cl) areas (illustrated in A and F in Fig. 8). The
initial intrastriatal 6-OHDA lesion depleted the TH-positive
ﬁbres in the rostral striatum with  80%, while in the caudal
striatum  90% of the DA ﬁbres were lesioned (B and D,
Intrastriatal+Sham). The spared ﬁbres in the rostral region
were mainly located in the medial and ventral parts of the
striatum, and the rostro–dorsolateral regions of the striatum
showed less than 10% spared ﬁbres (C, Intrastriatal+Sham).
The second 6-OHDA lesion removed the remaining DA ﬁbres
and 54% of normal innervation remained in the four regions
evaluated (B–E, Intrastriatal+MFB). In the DA narrow and DA
wide groups signiﬁcant TH-positive ﬁbre reinnervation ( 12–
14% of normal) was observed around the graft, in the caudal
and caudal-lateral regions (D and E). The ﬁrst 6-OHDA lesion
resulted in a marginal loss of the serotonin ﬁbres ( 20%; G–J,
Intrastriatal+Sham). The second lesion further removed an
additional  10% of the SERT-positive ﬁbres (to  70% of
intact side) in the striatum (G–J, Intrastriatal+MFB). In the 5-
HT and DA wide groups an extensive SERT-positive hyperin-
nervation was evident in the striatum at all levels (143–238%
and 139–246% of intact side in the intrastriatal+Sham and
intrastriatal+MFB groups respectively; G–J). In contrast, the
DA narrow group, which contained no serotonin neurons,
showed no increased SERT-positive innervation at any level.
Ash indicate different from other groups; Asterisk indicate dif-
ferent from Les-Ctrl (L-DOPA) group. A and F: One-way
ANOVAs F(2,42)=30.30, P50.0001 and F(2,42)=25.13,
P50.0001 respectively; D and E: One-way ANOVAs
F(3,28)=2.91, P=0.05 and F(3,28)=3.55, P=0.03/
F(3,28)=4.85, P=0.009 and F(3,28)=5.19, P=0.007 for
Intrastriatal+Sham/Intrastriatal+MFB and D and E, respec-
tively; (G–J) One-way ANOVAs F(3,28)=11.73, P50.0001,
F(3,28)=9.04, P=0.0003, F(3,28)=16.69, P50.0001 and
F(3,28)=13.59, P50.0001/F(3,27)=8.47, P=0.0005,
F(3,27)=13.83, P50.0001, F(3,27)=9.05, P=0.0003 and
F(3,27)=8.28, P=0.0006 for Intrastriatal+Sham/
Intrastriatal+MFB and G–J, respectively. All ANOVAs were
followed by Tukey HSD analysis (A and F) or Dunnett’s control
test (B–E, G–J).
330 | Brain 2009: 132; 319–335 T. Carlsson et al.therapeutic window of L-DOPA medication (Mouradian et al.,
1990; Obeso et al., 2000). Similarly, the low-level dyskinesia
seen in the partially lesioned rats (in Stages I and II of the experi-
ment) increased both in magnitude and severity when the residual
striatal DA innervation was removed by the second lesion (Stage
III). The DA neuron-rich grafts had a marked dampening effect on
dyskinesia present at the time of transplantation, as seen earlier
(Lee et al., 2000; Steece-Collier et al., 2003; Carlsson et al., 2006,
2007; Lane et al., 2006; Maries et al., 2006), and they were also
able to block the increase in dyskinesia induced by the second
DA lesion, as well as the increase in striatal FosB expression that
is closely linked to the development of dyskinesia in L-DOPA-trea-
ted animals. In the DA narrow and DA wide graft groups dyski-
nesias remained on a low-to-moderate level, also after removal of
the remaining DA afferents, without any clear signs of the more
severe, dystonia-like axial dyskinesias (for further explanation of
the axial component see Materials and Methods section). Dyski-
nesia induced by direct stimulation of postsynaptic DA receptors by
a low dose of apomorphine was almost completely eliminated. The
results obtained in the amphetamine-induced rotation and fore-
limb-use tests, as well as the normalization of DA receptor super-
sensitivity in the apomorphine rotation test, indicate that a
functional DA innervation had been re-established from the
grafted DA neurons in these rats.
The changes induced by serotonin-rich grafts were quite differ-
ent: The low-level dyskinesia present in the partially lesioned rats
at the time of transplantation increased after transplantation in the
5-HT group, as reﬂected in an average 2-fold increase in total AIM
score and the appearance of the more severe, dystonia-like, axial
dyskinesia during Stage II of the experiment. Further, there was a
dramatic increase in both the magnitude and severity of dyskinesia
after the second DA lesion (Stage III). The serotonin transplants
did not induce any functional improvement in the amphetamine-
induced rotation and cylinder tests, the postsynaptic DA receptors
remained supersensitive (as assessed by the apomorphine- and
L-DOPA-induced rotation tests), and both apomorphine-induced
dyskinesia and cellular FosB expression remained as high, or
increased, compared with the dyskinetic lesion-only controls.
Interaction of the serotonin neurons
with the spared DA innervation of the
host
In the rat Parkinson model the magnitude, and also the expression
pattern, of L-DOPA-induced dyskinesia is critically dependent on
an interaction between the spared DA innervation and the intrinsic
serotonin afferents (Carta et al., 2007). In the lesioned controls
studied here the dyskinesia scores recorded in the animals with
partial intrastriatal 6-OHDA lesions increased 3-fold when the resi-
dual DA innervation was removed. Consistent with previous ﬁnd-
ings (Carta et al., 2007) all components of AIMs (orolingual, limb,
axial and locomotive) were completely eliminated by the 5,7-DHT
lesion, indicating that the dyskinetic movements were triggered
almost exclusively by DA formed and released by the intrinsic
serotonin afferents.
In rats with serotonin-rich transplants the grafted serotonin neu-
rons provided a widespread serotonergic hyperinnervation of the
host striatum, with a terminal density that was up to 2.5-fold
higher than normal. In the partially lesioned rats the impact of
this graft-derived serotonergic hyperinnervation was rather
modest: dyskinesia was increased above that seen in the lesion-
only controls, but remained at a low-to-moderate level, i.e. at a
total AIM score of below 400. Removal of the residual intrinsic DA
innervation, however, caused a dramatic increase in both the mag-
nitude and severity of L-DOPA-induced dyskinesia, with the
appearance of intense axial movements, and total AIM scores
that exceeded 1100. These data indicate that the spared intrinsic
DA innervation has an important dampening effect on the sero-
tonin-dependent dyskinesias, and that DA released from serotonin
terminals is detrimental in animals where the striatum is comple-
tely denervated. At that stage of the disease, the serotonin term-
inals may be the only source of DA release in the striatum, at least
when low doses of L-DOPA are administered as in the present
experiment.
The mechanism underlying this dampening effect has most
probably both a pre and a postsynaptic component. On the pre-
synaptic side, the swings in extracellular levels of L-DOPA-derived
DA, released as a false transmitter from the serotonin terminals,
will be counteracted by an active re-uptake of DA from the extra-
cellular space by the remaining DA terminals. In this situation the
interplay between the serotonin and DA terminals may, in fact, be
functionally beneﬁcial in that the serotonin terminals can provide
additional sites for synthesis and storage of L-DOPA-derived DA
that can be utilized by the residual DA terminals. On the post-
synaptic side, the residual DA innervation, with the help of the
exogenously supplied L-DOPA, will be able to maintain the post-
synaptic DA receptors in a normo-sensitive state, as indicated by
the absence of apomorphine-induced rotation in the partially
lesioned rats. The postsynaptic DA receptor supersensitivity that
developed after the removal of the remaining DA afferents by the
MFB lesion (as reﬂected by the marked increase in apomorphine-
induced turning and cellular FosB expression) is likely to make the
striatal neurons prone to elicit abnormal behavioural responses.
The dysregulated, pulsatile release of DA from the graft-derived
serotonin terminals was clearly non-functional (in the ampheta-
mine-induced rotation and cylinder tests) and, interestingly, also
unable to normalize DA receptor supersensitivity (in the apomor-
phine-induced rotation test) and striatal FosB expression. In situa-
tions when the residual DA innervation has degenerated,
therefore, DA released from serotonin terminals will trigger more
severe dyskinetic responses by acting on supersensitive DA recep-
tor sites, in the absence of any beneﬁcial effects of the L-DOPA
treatment.
Interaction between DA and serotonin
neurons in grafts containing a mixture
of both neuron types
In one of the transplant groups, the DA wide group, the dissection
of the VM tissue was made so as to obtain grafts that contained
both DA and serotonin neurons in large numbers. As in our
Serotonin-neuron-induced dyskinesia Brain 2009: 132; 319–335 | 331Fig. 8 TH and SERT immunohistochemistry. After the ﬁrst intrastriatal 6-OHDA lesion (A) the caudal part of the striatum was
severely depleted, while spared TH-positive innervation could be observed in the rostral (in particular in medial and ventral) regions.
The second 6-OHDA lesion, placed in the MFB, (B) removed the remaining DA ﬁbres and left the striatum completely denervated.
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the TH-positive innervation in the caudal striatum to 12–14% of
normal, and increased the host serotonin innervation to levels up
to 2-fold, above normal, in particular, in the rostro–dorsolateral
part of the striatum, and they were as efﬁcient as the DA narrow
grafts (i.e. the transplants containing DA neurons only) in restoring
DA-dependent motor behaviour in the cylinder and amphetamine-
induced rotation tests. Most notably, however, these mixed grafts
were as efﬁcient as the DA neuron only grafts in the dampening
of L-DOPA-induced dyskinesia, both in partially lesioned animals
(Stage II) and after removal of the remaining host DA afferents
(Stage III).
Interestingly, the dampening effect on dyskinesia in the rats
with DA wide grafts, i.e. grafts with mixed DA and serotonin
neurons, was opposite to the worsening seen in rats with grafts
containing serotonin neurons only (i.e. the 5-HT graft group). It
seems unlikely that this difference was due to any major differ-
ences in number of serotonin neurons in the grafts, or the extent
of graft-derived serotonin innervation of the host striatum since
several of the animals in the DA wide group, that showed marked
reductions in L-DOPA-induced dyskinesia, had similar numbers of
serotonin neurons in the graft and similar levels of SERT-positive
striatal innervation as animals in the 5-HT graft group that showed
the opposite effect. This indicates that the effect of the graft-
derived serotonin innervation is detrimental only in the absence
of a signiﬁcant functional dopaminergic input. Similar to the
spared host DA innervation, as discussed above, we propose
that the DA innervation derived from the DA neurons in the
graft will be effective in blocking the pro-dyskinetic effect of
grafted serotonin neurons by a combination of efﬁcient re-
uptake of L-DOPA-derived DA from the extracellular space
(which will help to dampen the excessive swings in DA released
from the serotonin terminals), and reversal of postsynaptic DA
receptor supersensitivity in the re-innervated areas. This is sup-
ported by the observations that dyskinesia induced by direct sti-
mulation of the postsynaptic receptors, by a low dose of
apomorphine, was much reduced in the DA wide group, and
that apomorphine- and L-DOPA-induced turning, and increased
FosB expression in the striatal projection neurons, were almost
completely eliminated in the DA wide graft group (but increased
in the 5-HT graft group).
Clinical implications
The results show that the development of L-DOPA-induced dyski-
nesia in the rat Parkinson’s disease model depends on a close
interaction between the dopaminergic and serotonergic afferents.
In non-grafted 6-OHDA lesioned rats systemic L-DOPA adminis-
tration induces AIMs only when the loss of DA neurons in the SN
is greater than  80% and the loss of DA innervation in the lateral
part of the striatum exceeds  90% (Winkler et al., 2002). This
suggests that when dyskinesias is induced in the rat model by
low L-DOPA doses (6–12mg/kg; which corresponds to the doses
used clinically), as little as 10% of the normal DA innervation
density in the critical, lateral dyskinesia-triggering part of the cau-
date–putamen may be sufﬁcient to buffer the swings in DA
released from the serotonin terminals. Since the DA innervation
in the intact striatum is some 15- to 20-times higher in density
than the serotonin ones (as judged by the tissue levels of DA and
serotonin; see Carta et al., 2007) this suggests that a DA:serotonin
terminal ratio of about 1:1, or higher, would be sufﬁcient to keep
the dyskinesias in check. Indeed, when this situation is met DA
synthesized and released from the serotonin terminals might be
beneﬁcial and contribute positively to the therapeutic efﬁcacy of
L-DOPA treatment. It is interesting to compare these values,
obtained in rats, with the situation in Parkinson’s disease patients.
Similar to the rat striatum the DA:serotonin ratio in the putamen
of control human cases is about 20:1 (Kish et al., 2008). In
advanced cases of Parkinson’s disease the putaminal DA levels
are typically reduced by more than 90% (by 98% in the Kish
et al., 2008 study), while the loss of putaminal serotonin innerva-
tion (as assessed by levels of serotonin, SERT and tryptophan
hydroxylase) is less, and also more variable (30–65%). As a
result, the DA:serotonin ratio is reduced to an average of about
1:1 (Kish et al., 2008), i.e. within the range where dyskinesias
would be expected to be held in check by the residual DA inner-
vation. Kish et al. did not observe any difference in putaminal
DA:serotonin ratio in patients with or without recorded dyskine-
sias, which may be explained by the fact that the tissue samples
used for analysis included the whole putamen. If the induction of
L-DOPA-induced dyskinesias is critically dependent on DA released
in a particular, dyskinesia-prone sub-region of the putamen (as is
the case in rodents; see Cenci et al., 1998) then the overall
putaminal tissue levels may mask important regional differences
in the DA and serotonin innervation densities that may determine
the patient’s sensitivity to develop dyskinetic side-effects.
In grafted animals, we propose that the impact of serotonin
neurons in the transplant will depend on the density of graft-
derived and/or spared intrinsic DA innervation in the striatum,
and whether the relative density of the serotonin innervation in
the critical part of the striatum will be kept below this critical
threshold. In animals with partial 6-OHDA lesions (with an overall
80–90% reduction in striatal DA innervation) the serotonin-only
transplants (5-HT graft group) produced a 2- to 3-fold increase in
the SERT-positive innervation in the caudate–putamen, corre-
sponding to a DA:serotonin innervation ratio in the range of 1:1
to 1:2. In these previously mildly dyskinetic animals the AIMs
scores increased about 2.5-fold, but were still kept in the low-
to-moderate range. In the DA wide group, transplants contained
In the animals receiving DA-rich grafts (DA narrow and DA wide) a TH-positive reinnervation could be observed around the graft core
in the caudal aspect of the head of the striatum (C and D), while in the group receiving serotonin grafts (5-HT), with only few
included TH-positive neurons in the grafts, the striatum remained completely denervated (E). In the animals with serotonin-rich
grafts (5-HT and DA wide), strong hyperinnervation was observed in the whole striatum, in particular in the Rdl region (I and J).
A distinct, localized increase in SERT-positive ﬁbres was observed in the ventrolateral striatum in many of the non-grafted lesion
controls, and in the DA narrow graft group (marked by asterisks in F, G and H). Scale bar in J represents 3mm.
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TH-positive innervation density was  15% of normal, while the
SERT-positive innervation was increased about 2-fold above
normal, suggesting that the relative densities of the DA and ser-
otonin innervations of the host striatum was maintained within the
critical 1:1 range. Consequently, these animals displayed low or no
dyskinesias also after the second 6-OHDA lesion.
The implications of these ﬁndings for the appearance of
dyskinesia in grafted Parkinson’s disease patients are 3-fold:
(i) In patients with transplants that contain DA neurons but no
or very few serotonin neurons the grafts should retard the
development of L-DOPA-induced dyskinesia, and reduce already
established dyskinesias, provided that the graft-derived DA
innervation of the host putamen is extensive enough to exceed
that of the intrinsic serotonin innervation; (ii) In patients with
grafts that contain serotonin neurons in excess of the dopaminer-
gic ones the impact on dyskinesia will depend on the extent
of degeneration of the host nigrostriatal system or the extent
of reinnervation of the host striatum by the graft-derived
DA neurons. The excess innervation provided by the grafted ser-
otonin neurons will promote the development of L-DOPA-induced
dyskinesias, and also make already established dyskinesias worse,
in case the DA innervation of the dyskinesia-triggering sub-region
of the putamen is reduced below the critical threshold and (iii) In
patients with more advanced disease (i.e. extensive degeneration
of the intrinsic putaminal DA innervation) the impact of mixed DA
and serotonin grafts will depend on the ability of the grafted DA
neurons to provide a widespread innervation of the host puta-
men, in particular of those sub-regions of the putamen that are
primarily involved in the induction of AIMs in dyskinetic patients.
Interestingly, in a recent study of the brains of two VM-trans-
planted Parkinson’s disease patients (Mendez et al., 2008) these
long-term surviving grafts were seen to contain DA and serotonin
neurons in roughly equal numbers (as assessed by TH and trypto-
phan hydroxylase immunohistochemistry; O. Isacson, personal
communication). Consistent with the observations in the DA
wide graft group in the present study, it seems that L-DOPA-
induced dyskinesia had remained low in these patients still by 21
months after transplantation.
Although we did not observe any spontaneous graft-induced
dyskinesias in the present study, this experimental design does
not provide evidence to rule out the possibility that serotonin
neurons may play a role in the development of graft-induced
off-state dyskinesia in grafted patients. Observations in trans-
planted patients (Freed et al., 2001; Ma et al., 2002) and 6-
OHDA lesioned rats (Steece-Collier et al., 2003; Carlsson et al.,
2006, 2007; Lane et al., 2006; Maries et al., 2006) indicate that
this type of dyskinesia is induced by dysregulated release of DA,
and/or excessive activation of supersensitive DA receptors, caused
by an uneven, patchy graft-derived DA innervation of the host
striatum. It seems possible that an unfavorable DA:serotonin
innervation ratio could contribute to this effect by maintaining
the postsynaptic DA receptors in a supersensitive state.
Moreover, the excessive swings in extracellular DA generated
from graft-derived serotonin terminals could be the driving force
to induce a hypersensitive state of the postsynaptic receptors that
will make the striatal targets prone to generate AIMs even in the
absence of any exogenous L-DOPA. Investigations of the presence
and extent of serotonin innervation in the striatum of patients with
graft-induced dyskinesias, e.g. by PET imaging with ligands for the
serotonin transporter, may help to clarify this point.
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